Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2023-12-12

FDA Approved: TROGARZO — Supplemental Application (Theratechnologies Inc.)

View source ↗

Summary

FDA approved a supplemental application for TROGARZO (ibalizumab) filed by Theratechnologies, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Trogarzo (ibalizumab)

Snippet

SUPPL AP for TROGARZO (IBALIZUMAB)